TELA Bio, Inc. (TELA)

Market Cap	77.53M
Revenue (ttm)	71.22M
Net Income (ttm)	-43.44M
Shares Out	39.55M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,267
Open	2.090
Previous Close	1.930
Day's Range	1.970 - 2.130
52-Week Range	0.865 - 5.175
Beta	0.90
Analysts	Strong Buy
Price Target	6.00 (+203.03%)
Earnings Date	Aug 11, 2025

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 209
• Stock Exchange: NASDAQ
• Ticker Symbol: TELA
• Website: https://www.telabio.com

Financial Performance

In 2024, TELA Bio's revenue was $69.30 million, an increase of 18.56% compared to the previous year's $58.45 million. Losses were -$37.84 million, -18.91% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for TELA stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 203.03% from the latest price.

Price Target

$6.0

(203.03% upside)

Analyst Consensus: Strong Buy